107 related articles for article (PubMed ID: 10667347)
21. CGP57698: a structurally simple, highly potent peptido-leukotriene (pLT) antagonist of the quinoline type.
von Sprecher A; Gerspacher M; Beck A; Anderson GP; Niederhauser U; Subramanian N; Ball HA; Gentsch C; Vassout A; Felner A; Bittiger H; Hauser K; Giese K; Kraetz J; Bray MA
Adv Exp Med Biol; 1997; 433():169-72. PubMed ID: 9561127
[No Abstract] [Full Text] [Related]
22. Inhaled montelukast inhibits cysteinyl-leukotriene-induced bronchoconstriction in ovalbumin-sensitized guinea-pigs: the potential as a new asthma medication.
Muraki M; Imbe S; Sato R; Ikeda Y; Yamagata S; Iwanaga T; Tohda Y
Int Immunopharmacol; 2009 Oct; 9(11):1337-41. PubMed ID: 19706339
[TBL] [Abstract][Full Text] [Related]
23. Treatment of asthma with antileukotrienes: first line or last resort therapy?
Dahlén SE
Eur J Pharmacol; 2006 Mar; 533(1-3):40-56. PubMed ID: 16510137
[TBL] [Abstract][Full Text] [Related]
24. Leukotriene C4 induces bronchoconstriction and airway vascular hyperpermeability via the cysteinyl leukotriene receptor 2 in S-hexyl glutathione-treated guinea pigs.
Yonetomi Y; Sekioka T; Kadode M; Kitamine T; Kamiya A; Matsumura N; Fujita M; Kawabata K
Eur J Pharmacol; 2015 May; 754():98-104. PubMed ID: 25704617
[TBL] [Abstract][Full Text] [Related]
25. [Mechanisms of action of cysteinyl leukotriene receptor antagonist and progresses in relevant studies in children with asthma].
Dong L
Zhonghua Er Ke Za Zhi; 2005 Apr; 43(4):266-8. PubMed ID: 15924717
[No Abstract] [Full Text] [Related]
26. Leukotriene D4-induced hypoxaemia in asthma is mediated by the cys-leukotriene1 receptor.
Casas A; Gómez FP; Dahlén B; Roca J; Barberà JA; Dahlén SE; Rodríguez-Roisin R
Eur Respir J; 2005 Sep; 26(3):442-8. PubMed ID: 16135725
[TBL] [Abstract][Full Text] [Related]
27. Montelukast causes prolonged, potent leukotriene D4-receptor antagonism in the airways of patients with asthma.
De Lepeleire I; Reiss TF; Rochette F; Botto A; Zhang J; Kundu S; Decramer M
Clin Pharmacol Ther; 1997 Jan; 61(1):83-92. PubMed ID: 9024176
[TBL] [Abstract][Full Text] [Related]
28. Involvement of cysteinyl leukotriene receptors in angiogenesis in rat thoracic aortic rings.
Xu L; Zhang L; Liu L; Fang S; Lu Y; Wei E; Zhang W
Pharmazie; 2010 Oct; 65(10):750-4. PubMed ID: 21105577
[TBL] [Abstract][Full Text] [Related]
29. A selective cysteinyl leukotriene receptor 2 antagonist blocks myocardial ischemia/reperfusion injury and vascular permeability in mice.
Ni NC; Yan D; Ballantyne LL; Barajas-Espinosa A; St Amand T; Pratt DA; Funk CD
J Pharmacol Exp Ther; 2011 Dec; 339(3):768-78. PubMed ID: 21903747
[TBL] [Abstract][Full Text] [Related]
30. Expression of CysLT2 receptors in asthma lung, and their possible role in bronchoconstriction.
Sekioka T; Kadode M; Fujii M; Kawabata K; Abe T; Horiba M; Kohno S; Nabe T
Allergol Int; 2015 Oct; 64(4):351-8. PubMed ID: 26433531
[TBL] [Abstract][Full Text] [Related]
31. Agonist- and T(H)2 cytokine-induced up-regulation of cysteinyl leukotriene receptor messenger RNA in human monocytes.
Shirasaki H; Seki N; Fujita M; Kikuchi M; Kanaizumi E; Watanabe K; Himi T
Ann Allergy Asthma Immunol; 2007 Oct; 99(4):340-7. PubMed ID: 17941281
[TBL] [Abstract][Full Text] [Related]
32. The cysteinyl-leukotriene-1 receptor antagonist zafirlukast is a potent secretagogue in rat and human airways.
Schmidt R; Staats P; Groneberg DA; Wagner U
Eur J Pharmacol; 2005 Dec; 527(1-3):150-6. PubMed ID: 16310765
[TBL] [Abstract][Full Text] [Related]
33. Combined Inhibition of Histamine H1 Receptors and Leukotrienes Reduces Compound 48/80-Induced Contraction of the Human Bronchus in vitro.
Benko R; Molnar TF; Szombati V; Benkö I; Bartho L
Pharmacology; 2015; 96(5-6):253-5. PubMed ID: 26394300
[TBL] [Abstract][Full Text] [Related]
34. Functional characterisation of receptors for cysteinyl leukotrienes in smooth muscle.
Jonsson EW
Acta Physiol Scand Suppl; 1998 Mar; 641():1-55. PubMed ID: 9597121
[TBL] [Abstract][Full Text] [Related]
35. Role of cysteinyl leukotrienes in adenosine 5'-monophosphate induced bronchoconstriction in asthma.
Rorke S; Jennison S; Jeffs JA; Sampson AP; Arshad H; Holgate ST
Thorax; 2002 Apr; 57(4):323-7. PubMed ID: 11923550
[TBL] [Abstract][Full Text] [Related]
36. Discovery of OT4003, a novel, potent, and orally active cys-LT1 receptor antagonist.
Tvaermose-Nielsen O; Rachlin S; Dannacher H; Björkling F; Kirstein D; Bramm E; Nielsen CK; Mortensen JT; Binderup L
Bioorg Med Chem; 1997 Feb; 5(2):415-27. PubMed ID: 9061206
[TBL] [Abstract][Full Text] [Related]
37. Cysteinyl leukotriene receptor (CysLT) antagonists decrease pentylenetetrazol-induced seizures and blood-brain barrier dysfunction.
Lenz QF; Arroyo DS; Temp FR; Poersch AB; Masson CJ; Jesse AC; Marafiga JR; Reschke CR; Iribarren P; Mello CF
Neuroscience; 2014 Sep; 277():859-71. PubMed ID: 25090924
[TBL] [Abstract][Full Text] [Related]
38. Leukotriene receptor antagonist as a novel tocolytic in an in vitro model of human uterine contractility.
Corriveau S; Rousseau É; Blouin S; Pasquier JC
Eur J Obstet Gynecol Reprod Biol; 2014 Jun; 177():77-83. PubMed ID: 24735655
[TBL] [Abstract][Full Text] [Related]
39. [Leukotriene modifiers].
Minoguchi K; Adachi M
Nihon Rinsho; 2001 Oct; 59(10):1979-85. PubMed ID: 11676142
[TBL] [Abstract][Full Text] [Related]
40. Protective effect of high-dose montelukast on salbutamol-induced homologous desensitisation in airway smooth muscle.
Fogli S; Stefanelli F; Martelli A; Daniele S; Testai L; Calderone V; Trincavelli ML; Martini C; Breschi MC
Pulm Pharmacol Ther; 2013 Dec; 26(6):693-9. PubMed ID: 23810957
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
